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Since up to 80 percent ofpregnant women and 30 percent ofneonates may becolonized with
genital mycoplasmas, it is difficult to determine whether true infection occurs. The antibody
responses to eight serotypes of U. urealyticum were assessed in mothers and infants in 21 cases
of neonatal respiratory disease (RD) and 24 normal cases. Among the normal population of
mothers and infants, a titer of 2 1:32 occurred in 0.25 percent (1/394). In mother-infant
paired titers, a fourfold difference occurred in 2.6 percent (5/192). Among 54 RD neonates,
55.6 percent had a titer of a 1:32 compared to only 4.2 percent of normal neonates
(p < .001). Fourfold elevations in antibody titers of > 1:32 were observed in the neonate in
52.4 percent ofRDcases compared to0 perecnt of24 normal pairs (p < .001) and in 28.6 per-
cent of mothers of RD neonates compared to 0 percent in normal cases (p = .013). We ob-
served that 43.3 percent of RD neonates with titers a 1:32 died compared to 16.6 percent of
RD neonates exhibiting no elevation of antibody response over the maternal level. Among the
six who died, 66.7 percent of neonates and 16.7 percent of their mothers had elevated titers,
compared to 33.3 percent of 15 surviving infants and 40.0 percent of their mothers. These
elevated antibody responses strongly support the concept that U. urealyticum causes infection
in the perinatal period in association with neonatal respiratory disease. Since the elevation in
titers was detected close to delivery in many cases, the infection may occur in utero.
INTRODUCTION
Asymptomatic mycoplasma colonization occurs in 6-75 percent of adults and up
to 80 percent of pregnant women. Newborns are colonized at birth in 15-33 percent
of cases [1]. The presence of Ureaplasma urealyticum and/or Mycoplasma hominis
in placentas is associated with chorioamnionitis, low birth weight, and a signifi-
cantly higher rate of spontaneous abortion, prematurity, perinatal morbidity, and
mortality [1-4]. Mycoplasmas have been isolated from amniotic fluid [1,5] and are
associated with spontaneous abortion and congenital pneumonia [1-11].
Mycoplasmas from the genital tract have been associated with fetal pneumonia in
spontaneous abortion and congenital pneumonia in neonates based on the isolation
of the organism and histological evidence of inflammation in the lung [6-10]. In a
recent case ofcongenital pneumonia based on isolation and immunospecific staining
of the lung tissue, intrauterine infection was confirmed by the presence of an
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All rights of reproduction in any form reserved.elevated antibody titer at birth and the presence of IgM specific antibody at 74 hours
of age, suggesting infection began in utero [11]. Spontaneous abortion and "weak
calf syndrome" (with respiratory distress) were also observed in bovines infected in
pregnancy with U. diversum isolated from an aborted calf [12].
The possibility of intrauterine infection has been difficult to assess because isola-
tion of the organism does not distinguish between intra-partum colonization and
true infection. In this paper, serological data on infants born with respiratory




Antibody levels were determined on paired mother-infant sera from (a) 24 normal
healthy deliveries taken at birth, and (b) 21 pairs plus 33 neonates who were born
with respiratory disease (RD) of unknown etiology which was fatal or developed a
protracted course. These neonates were born between 25-40 weeks ofgestation with
sera drawn one to 20 days after delivery.
Serology
The paired sera were assayed simultaneously by a modified metabolic inhibition
test [13,14] for eight serotypes of U. urealyticum. The strains used were as follows:
Serotype 1 (strain 7), 2 (strain 23), 3 (strain 27), 4 (strain 58), 5 (strain 354), 6 (strain
Pi), 7 (strain Co), and 8 (strain T960-CX8). The strains were obtained from Dr. R.
Purcell at the National Institutes of Health, Bethesda, MD. Trypticase soy broth [3]
supplemented with 20 percent horse serum (K.C. Biologicals), 10 percent of fresh
yeast extract (25 percent w/v), 10 percent guinea pig serum (Gibco), 0.1 percent
urea, and 0.004 percent bromothymol blue was used. Each assay was done with 102
and 103 ccu/ml final concentration ofureaplasma as recommended by Lin [14]. The
initial dilution ofserum assayed was 1:8 since the organism and media were added at
the same time prior to incubation. The titer was read when the control cups contain-
ing ureaplasma without patient sera had changed 0.5 to 0.75 pH units. Plates were
read every 30 minutes once the color changes started. The endpoint was recorded as
the highest dilution of serum which inhibited growth and held constant for two con-
secutive readings (at least 30 minutes). Occasionally, when control cups did not turn
positive by day end, the plates were put at 30°C overnight. In most cases the titer
was the same. The plate was re-incubated at 36°C and read throughout the day. This
was essential since different serotypes grew at different rates. A pattern ofinhibition
of one dilution less for 103 ccu/ml from the reading at 102 ccu/ml was used as a
guide to control for spotting (lack of growth) in some cups of the microtiter plates.
Statistical Methods
Comparisons of the frequency of elevated titers used Chi2 or Fisher's exact test
when expected frequencies were small. Means of mothers and neonates in the RD
group were compared to normal mothers and neonates using a t-test and the
logarithm of the antibody titers. Titers of < 1:8 were taken as 1:4 to calculate
means. The means ofthe log titers have been converted back to the observed scale of
dilutions for presentation in Table 2 and Fig. 1.
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RESULTS
Comparison ofAntibody Titers to U. urealyticum in Normal Deliveries
Antibody titers to eight serotypes were determined on 24 randomly selected
mother-infant pairs with normal gestation, delivery, and healthy neonates. In the
192 paired MI tests, the mother's titer was equal to that of the neonate in 71.9 per-
cent of the assays. A twofold difference either way was observed in 25.5 percent. A
fourfold difference between the mother's and infant's titer to a given serotype was
observed in only 2.6 percent of cases. We therefore considered a titer fourfold
higher to be significantly elevated. Among the 394 titers obtained from normal
mothers and infants, a value of 2 1:32 was observed only once to one serotype (0.25
percent). This suggested that a titer 2 1:32 was above the normal range for a healthy
population.
Elevation ofAntibody Levels to U. urealyticum Serotypes
Antibody levels were compared in 21 RD neonates born between 25-42 weeks of
gestation and 24 normal neonates born at term and their mothers. A fourfold eleva-
tion in neonatal titer to at least one serotype was found in 47.6 percent of RD cases
compared to 16.7 percent of normal pairs (p = .056). Mothers of RD neonates ex-
hibited elevated titers over their infants at delivery in 33.3 percent ofcases compared
to 8.3 percent ofmothers ofnormal neonates (p = .084). Among the normal pairs,
the elevated titers were from < 1:8 to 1:16 whereas in the RD pairs the titers ranged
from < 1:8 to 1:128. However, in cases where the maximum titer was > 1:32, 52.4
percent of RD neonates exhibited elevations compared to 0 percent among normal
neonates (p< .001) and 28.6 percent of RD mothers had elevated titers compared to
0 percent of normal mothers (p = .013).
When the actual titers were compared, 57.1 percent(12/21) ofRD neonates with a
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Neonatal Mortality in Relation to Elevated Titers to U. urealyticum
Mean Gestational Age
(weeks) No. Proportion ofDeaths (No)
Infant Titer
. 1:64 32.3 11 6 (54.6)
1:32 32.0 19 7 (36.8)
< 1:16 30.9 24 9 (37.5)
4x Above Maternal Titer
To 1:64 or higher 37.0 1 1 (100)
To 1:32 33.5 4 1 ( 25)
To 1:16 29.5 4 1 ( 25)
No. 4x elevation 29.4 12 2 ( 17)
mean gestational age of 31.6 weeks had a titer .1:32 to at least one serotype of U.
urealyticum compared to 4.2 percent of normal term neonates (p<.001). Among
the mothers, 66.7 percent ofthose with RD neonates had at least one titer of . 1:32
compared to 0 percent of the normal mothers (p<.001).
Mortality Rate with U. urealyticum Infection
To correlate the effect of U. urealyticum as a cause ofsevere disease, the mortality
rate was assessed according to the degree of elevation in titers (Table 1). Among
neonates with atiter of 2 1:32, 43.3 percent (13/30) died. Among 10 neonates with a
4x elevation above the maternal level, 40 percent died compared to 16.6 percent of
12 whose titers were the same or less than their mother's. In the first group of six
who died, five had these elevated titers to serotype 8 whereas in the group of five
which survived only one had an elevated titer to serotype 8. In the six cases of death
with paired sera, 66.7 percent of neonates and only 16.7 percent ofthe mothers had
4x elevated titers. In comparison among the 15 survivors, 33.3 percent of neonates
and 40 percent of their mothers had elevated titers to at least one ureaplasma
serotype. These groups are not appropriate for statistical analysis because of group
size and the fact that an IgM specific titer of < 1:16 may be indicative of infection
in very premature neonates. In all cases where U. urealyticum infection was
suspected, the neonates were treated with erythromycin and/or chloramphenicol.
Comparison ofthe Mean Antibody Titers
To assess whether there was a difference in the antibody titers observed in the
neonates born with respiratory disease compared to normal neonates, the mean
titers were calculated for each serotype (Table 2). In the RD case, the neonates had
significantly elevated mean titers to serotypes 4, 7, and 8 when compared to the
mean titers of the normal neonates and slight but not significant elevations to
serotypes 3 and 6. Among the 21 pairs, ten neonates and seven mothers exhibited a
4x elevation with both observations occurring in three cases.
When the RD cases were assessed according to whether the infant survived or died
(Table 2), certain differences in the mean titers were observed. The mean titer to
serotype 3 was slightly elevated in all groups. With serotypes 4 and 8, the mean titers
were significantly higher among neonates who died than among the survivors. For
serotype 5, a significant elevation occurred only among the survivors. The elevation
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TABLE 2
Mean Antibody Titers in Neonates and Mothers to U. urealyticum Serotypes
Neonatal Respiratory Diseasea
Normal All Patients Survived Died
Pregnancy N = 54 (1); N = 32 (1) N 22 (1);
Serotype N = 24 N = 21 (M) N= 15 (M) N= 6 (M)
1 lb 4.9 4.7 4.7 4.7
M 4.8 5.1 5.5 4.1
2 I 6.0 7.5 7.2 8.1
M 5.7 7.2 7.0 8.1
3 I 6.2 8.2 9.1 7.1
M 6.2 8.8 9.2 8.1
4 1 4.5 6.5* 5.5 8.3*
M 4.2 5.0 5.0 5.0
5 I 4.9 6.2 7.2* 5.0
M 5.7 5.2 5.3 5.0
6 I 5.7 7.8 7.7 8.3
M 5.8 8.5 7.3 12.7
7 I 5.5 9.2* 9.3 9.2
M 5.2 6.1 6.1 6.4
8 I 4.9 9.3** 7.5 12.8*
M 5.0 6.8 6.1 9.0
aStatistical significance *p < .05, **p < .01
bI = Infant; M = Mother
in mean titer to serotype 6 among the mothers of RD cases is strongly influenced by
the high mean titer (12.7) among the six mothers whose neonates died (not
statistically significant). For serotypes 6 and 7, the mean titer is elevated among the
neonates to an equal degree in both groups.
Distribution ofAntibody Titers in Neonates and Mothers
The distribution of the antibody titers, for serotypes in which a significant dif-
ference was observed, are shown for neonates and their mothers in Fig. 1. When the
distribution is compared among the neonates for serotypes 4, 6, 7, and 8, there is a
trend toward higher mean titers in neonates with respiratory disease. The degree of
statistical significance is based on the comparison ofthe RD group, compared to the
normal group. Sterotypes4, 7, and8 arethe mostsignificant inthe RD group. When
the distribution is compared for the mothers' titers, the mean titers to serotypes 6, 7,
and 8 are elevated but not significantly.
Elevation in Antibody Titers by GestationalAge
Among the 54 RD neonates, titers of .1:32 to U. urealyticum serotypes were
evaluated according to gestational age. In the group of 14 neonates born between
22-27 weeks of gestation, 64.3 percent had a titer of 1:32 to at least one serotype.
Among 25 neonates of 28-35 weeks' gestation, 36.0 percent were elevated and
among 15 of those born after 36 weeks' gestation, 80.0 percent had elevated titers.
The incidence of titers of > 1:32 were all significantly higher than the 4.2 percent
observed in normal neonates.
569In the cases of the very premature neonates, 22-30 weeks' gestation, the elevation
in titers tended to be low, e.g., 1:8 to 16 or 1:8 to 1:32 for mother vs. neonate, but
with some neonates as high as 1:256. In the infants born after 30 weeks, the titers
ranged from 1:8 to 1:32 up to 1:8 to 1:128. Since the mothers can have high titers
due to IgG which crosses the placenta, a high neonatal titer may not be indicative of
neonatal infection.
DISCUSSION
U. urealyticum has been considered an infectious agent in pregnancy, leading to a
poor outcome [1-11], but a causal role is difficult to assess. Colonization may occur
before or after the death of the fetus, after an extended period of ruptured mem-
branes, or the organism may be aspirated during delivery. Second, the inflammatory
response in lungs and placenta may be due to other microorganisms not detected.
However, elevation in IgM antibodies to the same ureaplasma serotype isolated
from the lung [11] is indicative oftrue infection. In the bovine model, inoculation of
pregnant cows with U. diversum at five months of gestation resulted in abortion or
severe respiratory distress. The organism was isolated and an inflammatory response
was observed in the lungs, similar to that observed in humans [12]. These observa-
tions support the hypothesis that the living fetus may be infected with ureaplasmas
in utero.
In this study elevated antibody responses to specific U. urealyticum serotypes
were found in infants at delivery. A number ofsituations are therefore possible. The
mother had the infection prior to conception with circulating IgG antibody which
crossed to the fetus, resulting in equal titers. In the second group, infection is
established in the mother prior to conception or during pregnancy such that she has
or develops an antibody response of the IgM class. Because these antibodies do not
cross to the fetus, the mother has a higher titer than the neonate. In the third case,
infection occurs on the fetal side on the immunological barrier. The fetus develops its
own 1gM specific antibody response which does not cross to the maternal circula-
tion. The neonate, therefore, has an elevated titer over the maternal level. In a few
cases this elevated titer was proven to be IgM-specific [11; unpublished results].
Finally, the mother could have IgG plus IgM. The fetus acquires maternal IgG but
synthesizes its own IgM, which results in high titers in both mother and fetus. The
situation is complex because of the large number of serotypes which could elicit
these antibody responses. In one case, the mother had elevated titers to serotypes 6
and 7, while the neonate had elevated titers to serotypes 2 and 4.
The mean titers were assessed to determine which serotypes elicited a significant
antibody response. A small elevation in the mean titer was observed to serotype 3 in
both the normal and RD groups and was also found in the spontaneous abortion
group. Since 80 percent of the local population, whether fertile or infertile, carry
serotype 3 compared to 20 percent or less for the other serotypes [16], one would ex-
pect an antibody response comparable in all groups. In the RD cases, the neonates
had elevated titers to serotypes 4, 7, and 8, but the mothers did not to a significant
degree. In mycoplasma-positive women with a history of pregnancy loss (PL), the
maternal titers were elevated to serotypes 4 and 8, and to 6 and 8 in the neonates [15].
Since the significantly elevated antibody responses do not occur to serotype 3 but to
serotypes 4, 6, 7, and 8, the data suggest that serotype 3 may exist as a commensal
while serotypes 4, 6, and particularly 8 may be more pathogenic.
In abortion, U. urealyticum appears to play a causal role. An inflammatory
response in the lungs or lesion in the tracheal epithelium may or may not be observed
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[8]. In our studies, neonates of 22-28 wveeks' gestation exhibited fourfold higher
titers than their mothers. This fact supports the concept that the fetus is infected in
utero, eliciting its own immune response. In our studies of abortion associated with
genital mycoplasmas there is a marked trend in which 40 percent ofpregnancies are
lost later in the second trimester. Why some infected fetuses are live rather than
aborted or stillborn is not known. However, it is possible that those infants in whom
antibodies develop or who acquire antibodies from their mothers, cope with the in-
fection better, resulting in a live birth. Finally, among the healthy neonates of
erythromycin-treated PL mothers [17], theantibody response to serotype 8 was most
significant as it was for RD neonates who died. This fact suggests that erythromycin
therapy during gestation prevented severe disease in the fetus, resulting in healthy
neonates.
In conclusion, the development of an immune response to the presence of U.
urealyticum supports the concept that this organism is capable of causing
fetal/neonatal infection. Women may be colonized with U. urealyticum but exhibit
no clinical signs of disease. However, in certain women and during pregnancy, the
organism may cause infection in the mother and/or the fetus which results in abor-
tion, stillbirth, prematurity, and severe congenital pneumonia or chronic respiratory
disease in the neonate.
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